1. Home
  2. TNYA

as 03-31-2025 9:54am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.

Founded: 2016 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 113.6M IPO Year: 2021
Target Price: $8.60 AVG Volume (30 days): 6.1M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.31 EPS Growth: N/A
52 Week Low/High: $0.39 - $5.25 Next Earning Date: 03-10-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

TNYA Daily Stock ML Predictions

Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Tingley Whittemore TNYA Chief Medical Officer Mar 10 '25 Sell $0.54 7,398 $3,983.08 180,464
Ali Faraz TNYA Chief Executive Officer Mar 10 '25 Sell $0.54 9,741 $5,244.55 324,461
Higa Tomohiro TNYA SVP, Finance Mar 10 '25 Sell $0.54 2,482 $1,336.31 101,155
COLUMN GROUP III GP, LP TNYA 10% Owner Mar 5 '25 Buy $0.70 35,714,284 $24,999,998.80 49,313,559
GOEDDEL DAVID V TNYA Director10% Owner Mar 5 '25 Buy $0.70 35,714,284 $24,999,998.80 49,313,559

Share on Social Networks: